A Deep, Broad Pipeline to Address Unmet Patient Need
Our deep and broad pipeline contains multiple preclinical stage candidates for diseases with significant unmet need. We are moving with urgency to develop transformative medicines that have the potential to help improve the lives of millions of people around the world.
Secretome Platform
Exosomes are a subclass of Extracellular Vesicles (EV) produced and released by nearly every cell type in the human body and act as our bodies internal drug delivery mechanism. The cumulative cocktail of exosomes released by each cell type into their native environment is termed the cell's Secretome. Small Extracellular Vesicles (sEV), are of particular interest to Interactome Biotherapeutics.
Exosomes
Much like the cells in our bodies, exosomes contain a lipid bilayer that protects their cargo while also carrying embedded proteins and receptors that dictate which target cells the nanoparticle will interact with in the native tissue niche.
Ease of Administration
The cargo, surface receptors, and function of each exosome are dictated by the parent cell from which they are produced. Due to their size and stability, numerous options for administration are feasible including systemic, intraoral, topical, and intranasal delivery.
Immune silent drug delivery
Exosomes carry nucleic acids, proteins, and various signaling molecules and are non-immunogenic making them a viable option for immune silent drug delivery.
Native vs. Synthetic
Exosomes extracted from their endogenous tissue niche are termed native nanoparticles and can also be synthetic when engineered to carry targeted ligands or loaded with specific proteins, nucleic acids, or small molecules.
